DePuy Synthes touts improved functionality, shorter hospital stays with Attune knee

Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes late last week released new data on its Attune knee system from a study and internal report, touting potential benefits of the system. The company released data from a study of the Attune knee implant comparing it to preoperative baseline at six months. Data from the study indicated a statistically significant improvement in knee function for patients with the Attune knee as measured by the Knee injury and Osteoarthritis Outcome Score-Physical Function Short Form. Results were presented at the 2nd World Arthroplasty congress in Rome, the company said. The study examined 200 cases from The Netherlands, and determined that in 80% of those cases improvements on the KOOS-PS scale were realized within six months, with statistically significant improvements observed at intervals prior to six months. Pain and other patient reported outcome measures were also statistically significantly better at six months when compared to pre-operative baselines. DePuy Synthes also released data from an internally generated report summarizing a series of studies across a number of countries with differing healthcare systems, touting a reduced length of stay for Attune patients. The retrospective review looked to examine the connection between implant design and patient hospital length of stay, and took data from five real-world evidence studies conducted by the company to evaluate whether patients with the Attune knee had shorter LOS versu...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Orthopedics depuysynthes johnsonandjohnson Source Type: news